share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股sec公告 ·  06/06 00:31
牛牛AI助理已提取核心訊息
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 50,000 Class A shares of the company, with an aggregate market value of $421,000, on 06/05/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned transaction follows a series of sales over the past three months, where Gibson sold a total of 356,319 shares, amounting to gross proceeds of approximately $3.35 million.
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 50,000 Class A shares of the company, with an aggregate market value of $421,000, on 06/05/2024. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned transaction follows a series of sales over the past three months, where Gibson sold a total of 356,319 shares, amounting to gross proceeds of approximately $3.35 million.
Recursion Pharmaceuticals, Inc. 的一名高級職員和董事Christopher Gibson決定出售5萬股A類公司股票,總市值為421,000美元,交易日期為2024年6月5日。這些股份最初於2016年9月1日作為創始人股份獲得,是發行人提供的一種補償形式。這次計劃中的交易是在過去三個月中一系列的股份出售之後進行的,Gibson總共出售了356,319股,總收益約為335萬美元。
Recursion Pharmaceuticals, Inc. 的一名高級職員和董事Christopher Gibson決定出售5萬股A類公司股票,總市值為421,000美元,交易日期為2024年6月5日。這些股份最初於2016年9月1日作為創始人股份獲得,是發行人提供的一種補償形式。這次計劃中的交易是在過去三個月中一系列的股份出售之後進行的,Gibson總共出售了356,319股,總收益約為335萬美元。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。